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OBJECTIVE — Sulfonylureas have historically been analyzed as a medication class, which
maybeinappropriategiventhedifferencesinpropertiesinherenttotheindividualsulfonylureas
(hypoglycemic risk, sulfonylurea receptor selectivity, and effects on myocardial ischemic pre-
conditioning). The purpose of this study was to assess the relationship of individual sulfonyl-
ureas and the risk of overall mortality in a large cohort of patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — A retrospective cohort study was conducted
using an academic health center enterprise-wide electronic health record (EHR) system to
identify 11,141 patients with type 2 diabetes (4,279 initiators of monotherapy with glyburide,
4,325 initiators of monotherapy with glipizide, and 2,537 initiators of monotherapy with
glimepiride), 18 years of age with and without a history of coronary artery disease (CAD) and
not on insulin or a noninsulin injectable at baseline. The patients were followed for mortality by
documentationintheEHRandSocialSecurityDeathIndex.MultivariableCoxmodelswereused
to compare cohorts.
RESULTS — Nostatisticallysigniﬁcantdifferenceintheriskofoverallmortalitywasobserved
among these agents in the entire cohort, but we did ﬁnd evidence of a trend toward an increased
overall mortality risk with glyburide versus glimepiride (hazard ratio 1.36 [95% CI 0.96–1.91])
and glipizide versus glimepiride (1.39 [0.99–1.96]) in those with documented CAD.
CONCLUSIONS — Our results did not identify an increased mortality risk among the in-
dividual sulfonylureas but did suggest that glimepiride may be the preferred sulfonylurea in
those with underlying CAD.
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T
he University Group Diabetes Pro-
gram (UGDP) raised concern that
the administration of tolbutamide, a
ﬁrst-generation sulfonylurea, may in-
creasetheriskofcardiovasculardeath(1).
It was largely this uncertainty surround-
ing sulfonylureas that prompted the UK
Prospective Diabetes Study (UKPDS),
which itself did not support the sugges-
tion by the UGDP that sulfonylurea ther-
apy increased the risk of cardiovascular
mortality (2).
The proposed increased risk of car-
diovascular death largely went unex-
plained until reports surfaced suggesting
deleterious effects of some sulfonylureas
(glyburide), speciﬁcally on the ischemic
myocardium (impairment of ischemic
preconditioning and/or increased infarct
size)(3,4).Interestingly,thishasnotbeen
observed to be a class effect of the sulfo-
nylureas but an important difference
among individual sulfonylureas based
largely on their afﬁnity for the three iso-
formsofthesulfonylureareceptor(SUR1,
SUR2A, and SUR2B). SUR1 is largely
foundintheATP-dependentK
channels
(KATP channels) of -cells, whereas
SUR2A and SUR2B are largely found in
the KATP channels of cardiac and vascular
smooth muscle (5,6). Sulfonylureas spe-
ciﬁc for SUR1, so-called pancreatic-
speciﬁc sulfonylureas (tolbutamide,
chlorpropamide, gliclazide, and glipi-
zide), are speciﬁc for the pancreatic
-cells, and thus their effect is largely on
potentiatinginsulinsecretion(5,7).Non–
pancreatic-speciﬁc sulfonylureas (gliben-
clamide [glyburide] and glimepiride), in
addition to potentiating insulin secretion
viathe-cells,alsoexhibittheireffectson
cardiovascular and vascular smooth mus-
cle (7,8).
Although both glibenclamide (gly-
buride) and glimepiride have afﬁnity for
the SUR2 receptor (non–pancreatic spe-
ciﬁc), as determined by receptor interac-
tionstudies,glimepiridewasfoundnotto
impair ischemic preconditioning in rats
or in human experiments, whereas gliben-
clamide (glyburide) has been shown to
prevent ischemic preconditioning in hu-
mans (9–11). A recent cohort analysis by
Evans et al. (12) found no difference in
mortalitybetweenusersofpancreaticand
non–pancreatic-speciﬁc sulfonylureas;
however, grouping non–pancreatic-
speciﬁc sulfonylureas (glimepiride and
glibenclamide [glyburide]) together into
the same cohort, given their differing ef-
fectsonischemicpreconditioning,aswell
as their differing risk of hypoglycemia,
may be inappropriate (13).
We have previously reported an in-
creased risk of overall mortality with sul-
fonylurea monotherapy (14); however,
sulfonylureas were analyzed as a class (as
they have been historically). It is possible
that meaningful clinical differences could
exist between the different speciﬁc sulfo-
nylureas given their differences in phar-
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enterprise-wide electronic health record
(EHR), we were able to identify users of
a pancreatic-speciﬁc sulfonylurea, glipi-
zide, and two non–pancreatic-speciﬁc
sulfonylureas, glimepiride and glyburide
(glibenclamide), with different effects on
the ischemic myocardium (as well as dif-
fering risks of hypoglycemia), to deter-
mine whether differences in overall
mortality risk are present, as this would
have important implications when pick-
ing a sulfonylurea agent to control glyce-
mia in patients with type 2 diabetes,
especially those with documented coro-
nary artery disease (CAD).
RESEARCH DESIGN AND
METHODS— The methods of data
collection and analysis utilized in this
study are similar to those used in our pre-
viously published analysis investigating
adverse cardiovascular outcomes and
overall mortality risk with oral antidiabe-
tes anti-hyperglycemic monotherapy
(14).Thesourcepopulationwasobtained
from an EHR-derived clinical data repos-
itory at the Cleveland Clinic. This study
was approved by the institutional review
board.
Fortheperiod24October1998to12
October2006,weidentiﬁedallnewlyand
previouslydiagnosedpatientswithtype2
diabetesusingdocumentedICD-9andby
identifying patients with at least two en-
counters for diabetes after visiting the
Cleveland Clinic main campus or family
healthcentersandwhohadaprescription
for glyburide, glipizide, or glimepiride
entered into the EHR. Patients were strat-
iﬁed into three medication cohorts ac-
cording to the initial prescription entered
in the EHR at baseline. All patients were
18 years of age and had no history of
dialysis at baseline. Patients prescribed
insulin or other injectable diabetes medi-
cations (as monotherapy or in conjunc-
tion with oral agents) and those on
multiple oral agents at baseline were
excluded.
Follow-up
Follow-up began on the day after the ﬁrst
prescription of the qualifying study drug
was entered in the EHR. Patients entered
the cohort in a staggered fashion at any
time point between 24 October 1998 and
12October2006andfromthattimewere
followed until the date of mortality or
censoring. Patients with no observed
mortality were censored on the last clinic
encounterorthedateofextractionofvital
status from the Social Security Death In-
dex (SSDI) minus a 6-month lag, which-
ever came last.
Multivariable analysis
A multivariable analysis was utilized to
compare patients in each cohort, which
allowed us to adjust for differences in
baseline characteristics. Variables were
chosen and derived based on prior con-
siderations of their clinical relevance with
respect to the risk of mortality. The base-
line medical history variables chosen for
the overall mortality model were as fol-
lows: age, sex, race (Caucasian versus
non-Caucasian),ModiﬁcationofDietinRe-
nal Disease estimated glomerular ﬁltration
rate, hemoglobin A1C (A1C), BMI, systolic
blood pressure, diastolic blood pressure,
HDLcholesterol,LDLcholesterol,triglycer-
ides, smoking status, ACE therapy, or an-
giotensin receptor blocker therapy, aspirin
therapy, clopidogrel therapy, cholesterol-
lowering medication, new diabetes, CAD,
congestiveheartfailure,andmedianhouse-
hold income.
We were unable to use family history
or alcohol use as predictor variables due
to inconsistent documentation in the
EHR. The baseline variables were derived
from the EHR on the date closest to the
date of the ﬁrst sulfonylurea prescription
upto21daysafterbaseline.Missingbase-
line values were imputed by Chained
Equations (Mice) Package, version 1.16
forR,withoutregardtotheoutcomes,us-
ing regression techniques that included
all patients and all baseline values to pre-
dict the missing value.
Outcomes
Mortality was deﬁned by documentation
of death in the EHR or by being listed as
deceasedintheSSDI,whichallowedusto
identify those deceased individuals who
were lost to follow-up in the EHR.
Analysis
Analyses were performed using the sta-
tistical package R for Windows, version
2.8.1 (R Development Core Team
2008). Survival curves for mortality
were estimated with the Kaplan-Meier
procedure. Multivariable Cox propor-
tional hazards models were used to de-
rive hazard ratios for the three baseline
medication group comparisons. Re-
stricted cubic splines were used to relax
linearity assumptions for the continu-
ous variables. After adjustments were
madeforthebaselinecovariates,thefol-
lowing comparisons were made in all
patientsandrestrictedtopatientswitha
history of CAD:
● Glipizide versus glyburide
● Glipizide versus glimepiride
● Glyburide versus glimepiride
RESULTS— Using the EHR, we were
able to identify 4,279 initiators of mono-
therapywithglyburide,4,325initiatorsof
monotherapy with glipizide, and 2,537
initiators of monotherapy with
glimepiride,withandwithoutahistoryof
CAD,18yearsofageandnotoninsulin
or a noninsulin injectable at baseline. Ta-
ble 1 shows the distribution of the base-
line categorical variables for the entire
cohort as well as the subgroup of patients
with a history of CAD. The baseline con-
tinuous variables for both groups are dis-
played in Table 2.
Thecohortscontainedatotalof1,921
mortality events in the entire cohort (n 
11,141) and 322 in the subgroup with a
history of documented CAD (n  1,505).
Thesurvivalcurvesformortality,forboth
the entire cohort and for the subgroup
with a documented history of CAD, can
be seen in Fig. 1. There were 1,753 pa-
tients lost to follow-up in the EHR but
with vital status from the SSDI. The me-
dian follow-up was 2.4 years. The hazard
ratios with 95% CIs for the sulfonylurea
monotherapy comparisons for mortality
in the entire cohort, and the subgroup
with documented CAD, can be seen in
Table 3, after adjusting for baseline
variables.
Fortheperiod24October1998to12
October 2006, no difference in overall
mortality risk was found with glipizide
versus glyburide (hazard ratio 1.04 [95%
CI 0.94–1.15]), glipizide versus
glimepiride (1.05 [0.92–1.19]), or with
glyburide versus glimepiride (1.00
[0.89–1.14]). The subanalysis on pa-
tients with documented CAD revealed a
trend toward an increased overall mortal-
ity risk with glyburide versus glimepiride
(1.36 [0.96–1.91]) and glipizide versus
glimepiride (1.39 [0.99–1.96]). No dif-
ference (or trend) in overall mortality
within the subgroup was appreciated
with glipizide versus glyburide (1.03
[0.80–1.31]).
CONCLUSIONS — The present study
did not ﬁnd a statistically signiﬁcant dif-
ference in the risk of overall mortality
among the various treatment options,
suggesting that overall mortality is not
substantially inﬂuenced by the choice of
Pantalone and Associates
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of patients with documented CAD, a
trend toward an increased overall mortal-
ity risk with glyburide versus glimepiride
(hazard ratio 1.36 [95% CI 0.96–1.91]),
and surprisingly a trend toward an in-
creased risk of mortality with the SUR1-
speciﬁc sulfonylurea glipizide versus
glimepiride (1.39 [0.99–1.96]), were ob-
served, suggesting that glimepiride may
be the preferred sulfonylurea in those
with underlying CAD.
Although the study did not ﬁnd any
obvious difference in mortality risk be-
tween patients treated with speciﬁc sulfo-
nylureas, it is still possible that some
differences in mortality may truly exist.
There were signiﬁcantly fewer patients in
the CAD subanalysis, and the results
showed a strong trend toward a reduced
risk with glimepiride. It is quite possible
that a larger sample size would have de-
tectedasigniﬁcantdifference.However,it
would not be appropriate to perform a
post hoc power calculation since nonsig-
niﬁcantPvalueswilltendtobeassociated
with low power even if the sample size was
adequate (15). A clinically meaningful dif-
ferenceinmortalitywouldseemunlikelyin
the main analysis of all patients given the
Table 1—Baseline characteristics of the entire cohort and the subgroup of patients with CAD: categorical variables
Variable
Entire cohort Patients with CAD
Glimepiride Glipizide Glyburide Glimepiride Glipizide Glyburide
n 2,537 4,325 4,279 341 584 580
Male 1,370 (54.0) 2,422 (56.0) 2,408 (56.3) 233 (68.3) 400 (68.5) 419 (72.2)
Caucasian 2,044 (80.6) 3,237 (74.8) 3,207 (74.9) 285 (83.6) 488 (83.6) 477 (82.2)
Missing 86 (3.4) 129 (3.0) 131 (3.1) 10 (2.9) 10 (2.5) 11 (2.5)
Current smoker 254 (10.0) 459 (10.6) 425 (9.9) 34 (10.0) 49 (8.4) 50 (8.6)
Never 836 (33.0) 1,329 (30.7) 1,326 (31.0) 97 (28.4) 145 (24.8) 147 (25.3)
Passive 4 (0.2) 10 (0.2) 9 (0.2) 0 (0.0) 2 (0.3) 0 (0.0)
Quit 739 (29.1) 1,241 (28.7) 1,209 (28.3) 157 (46.0) 272 (46.6) 240 (41.4)
Missing 704 (27.7) 1,286 (29.7) 1,310 (30.6) 53 (15.5) 116 (19.9) 143 (24.7)
ACE/angiotensin receptor blocker inhibitors 1,344 (53.0) 2,213 (51.2) 2,220 (51.9) 245 (71.8) 378 (64.7) 382 (65.9)
Cholesterol-lowering medication 1,158 (45.6) 1,922 (44.4) 1,787 (41.8) 264 (77.4) 422 (72.3) 401 (69.1)
Plavix 221 (8.7) 333 (7.7) 322 (7.5) 90 (26.4) 101 (17.3) 113 (19.5)
Aspirin 669 (26.4) 1,029 (23.8) 1,017 (23.8) 178 (52.2) 277 (47.4) 263 (45.3)
CAD 341 (13.4) 584 (13.5) 580 (13.6) 341 (100) 584 (100) 580 (100)
Heart failure 197 (7.8) 319 (7.4) 326 (7.6) 82 (24.0) 141 (24.1) 150 (25.9)
New diabetes 249 (9.8) 411 (9.5) 280 (6.5) 47 (13.8) 71 (12.2) 43 (7.4)
Data are n (%).
Table 2—Baseline characteristics of the entire cohort and the subgroup of patients with CAD: continuous variables
Characteristic Glimepiride Glipizide Glyburide Missing
Entire cohort
Age (years) 65.6  13.1 66.1  13.3 67.8  13.1 0.0
BMI (kg/m
2) 31.1  6.5 30.8  6.8 30.8  6.7 49.7
Systolic blood pressure (mmHg) 134.8  20.8 135.1  21.8 135.9  22.1 24.5
Diastolic blood pressure (mmHg) 75.8  11.6 75.4  11.8 74.9  11.8 24.5
HDL (mg/dl) 45.4  14.4 45.6  14.2 45.9  15.4 56.0
LDL (mg/dl) 105.3  36.4 107.0  39.5 106.7  39.4 57.5
Triglycerides (mg/dl) 205.8  225.1 204.4  193.5 192.0  170.9 56.5
A1C (%) 7.5  1.8 7.7  1.9 7.6  1.8 54.5
MDRD eGFR truncated at 90 71.2  20.1 70.5  20.9 69.8  20.3 32.1
Zip median income ($) 46,216.0  14,888.5 43,786.1  14,737.8 43,477.7  14,583.6 0.1
Patients with CAD
Age (years) 68.8  11.2 70.3  10.8 71.2  10.3 0
BMI (kg/m
2) 30.2  6.0 29.9  6.0 30.3  6.4 41.2
Systolic blood pressure (mmHg) 133.4  21.4 130.6  22.1 132  23.7 12.6
Diastolic blood pressure (mmHg) 73.3  11.7 71.6  11.6 71.9  11.7 12.7
HDL (mg/dl) 43.7  12.9 43.4  13.2 44.2  14.4 34.0
LDL (mg/dl) 90.2  35.6 93.9  39.8 96.0  36.7 35.0
Triglycerides (mg/dl) 194.8  256.2 203.6  195.0 191.5  191.0 35.0
A1C (%) 7.3  1.4 7.5  1.6 7.3  1.5 44.1
MDRD eGFR truncated at 90 64.9  20.9 66.5  20.9 62.7  21.1 17.9
Zip median income ($) 47,551.4  15,925.4 44,756.9  15,225.5 44,871.9  15,716.3 0.1
Data are means  SD or percent. eGFR, estimated glomerular ﬁltration rate; MDRD, Modiﬁcation of Diet in Renal Disease.
Mortality risk with sulfonylurea monotherapy
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ard ratios) were all very close to 1.
Substantial multicollinearity in a re-
gression model can cause erroneous con-
clusions about the association between
individual variables (e.g., sulfonylurea
type)andtheoutcomeofinterest.Wecal-
culated the variance inﬂation factors for
the sulfonylurea comparisons. The vari-
ance inﬂation factors ranged from 1.93 to
1.95 in the entire cohort and 2.35 to 2.40
inthesubsetofpatientswithdocumented
CAD, which, according to Snee (16), sug-
gests substantial multicollinearity is un-
likely to be present.
There is a discrepancy within the lit-
erature regarding the risk of mortality
(overall or cardiovascular mortality) with
speciﬁc sulfonylureas. A recent report
found no substantial (statistically signiﬁ-
cant) differences in either 30-day or
1-year mortality in users of various sulfo-
nylureas after myocardial infarction (al-
though use of gliclazide monotherapy
showed a trend toward lower mortality
[hazard ratio 0.70 {95% CI 0.48–1.0}]),
suggesting that mortality is not substan-
tiallyinﬂuencedbythechoiceofsulfonyl-
urea (17). However, Khalangot et al. (18)
found that total mortality was lower for
gliclazide and glimepiride versus gliben-
clamide (glyburide) treatment (0.33
[0.26–0.41], P  0.001, and 0.605
[0.41–0.89], P  0.01, respectively) as
wellasareducedcardiovascularmortality
with gliclazide versus glibenclamide (gly-
buride) (0.29 [0.21–0.38], P  0.001).
The point estimates (hazard ratios) differ
greatly between the analyses conducted
by Horsdal et al. (17) and ourselves when
compared with the analysis by Khalangot
et al. (18), likely because Khalangot et al.
adjusted for few variables, many of which
may have caused confounding.
Thereareavarietyofproposedmech-
anisms for an increased mortality risk
with speciﬁc sulfonylureas. Despite the
differing effects of individual sulfonyl-
ureas on the SUR receptors and myocar-
dial ischemic preconditioning, there are
also differing effects regarding the risk of
hypoglycemia, independent of their SUR-
binding characteristics, which may be in-
ﬂuencing mortality (13). Among the
sulfonylureas studied in our analysis, gly-
buride is the most common agent associ-
ated with documented hypoglycemia
(19). Glyburide has been shown to con-
tinue to stimulate insulin secretion in the
setting of profound hypoglycemia to a
greater extent when compared with
glimepiride (20), in part because gly-
buride accumulates within the -cell
(21),unlikeothersulfonylureas,prolong-
inginsulinsecretion.Thus,hypoglycemia
could be playing a dominant role in in-
creasing the risk of mortality (more so
thandifferingselectivityandeffectsonthe
SUR receptors and ischemic precondi-
tioning, respectively), which has previ-
ously been reported with sulfonylureas,
speciﬁcally when compared with
metformin (14,22–24). Other than the
increased risk of hypoglycemia docu-
mented with glyburide (and the differ-
ences in other pharmacologic properties
inherent to the individual sulfonylureas:
SUR speciﬁcity and effects on ischemic
myocardium), glipizide, glimepiride, and
Figure 1—Overall mortality in the entire cohort (A) and subgroup with a documented history of
CAD (B), treated with sulfonylurea monotherapy. The decreasing numbers of patients at risk for
mortalityaresecondarytothestaggeredentryofthestudysubjects,notlosstofollow-up.Theﬁnal
status of all patients was ascertained via the SSDI.
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side-effect proﬁles.
The current study has limitations in-
herent to most retrospective studies. The
analysis was based on exposure to a med-
ication based on the initial prescription
entered in the EHR; however, there is no
documentation of compliance with the
prescribed medication. The prescribed
medication at baseline deﬁned which
medication group the patient belonged;
however, the medication exposure times
after baseline are unknown. Current clin-
ical practice procedures suggest that it is
more likely for additional agents to be
added to a baseline medication than to
switch from one class of medication to
another or from one sulfonylurea to an-
other. Approximately 70% of the cohort
remained on a single drug (baseline med-
ication) throughout their time in the
cohort.
The medication groups in our study
were not balanced with respect to base-
line variables and risk factors; however,
themultivariableanalysisadjustedforthe
differences in baseline variables and risk
factors that had the most relevance with
respect to the risk of mortality. Although
some covariates may have changed over
time, we would not anticipate these
changes to favor one speciﬁc sulfonylurea
versusanother(besidestheinherentchar-
acteristics of the individual agents).
Nonetheless, we could not adjust for dif-
ferences in unmeasured variables or
characteristics.
Sulfonylurea monotherapy was not
randomizedinthepresentstudy,soselec-
tionbiasmaybepresent.Itispossiblethat
one sulfonylurea may have been chosen
over another because of cost (the Food
andDrugAdministrationdidnotapprove
ﬁrst-time generic formulations of
glimepiride until November 2005), pa-
tient age, reduced glomerular ﬁltration
rate, risk of hypoglycemia, or perceived
differing effects on myocardial ischemic
preconditioning. However, although age
and renal insufﬁciency are associated
with an increased risk of death, the mul-
tivariableanalysisadjustedfordifferences
in baseline age and renal function, so this
should not explain the results. To take
into account the fact that generic
glimepiride was not available throughout
the entire duration of our study, we ad-
justed for socioeconomic status by in-
cluding the median household income
estimated from zip code data from the
2000censusinthemultivariableanalysis.
The strengths of the study include a
large cohort of patients followed up to 8
years and real-world effect of the medica-
tions in a diverse patient population. In
addition, we adjusted for many baseline
variables (accurately captured by the
EHR)thathavesubstantialeffectsonmor-
tality. Furthermore, linking our outcome
to the SSDI allowed us to capture mortal-
ity in those patients lost to follow-up in
the EHR.
Our results did not identify an in-
creased mortality risk among the individ-
ual sulfonylureas (glyburide, glipizide, or
glimepiride) in the entire cohort but did
ﬁnd evidence of a trend toward an overall
mortality reduction with glimepiride in
those with documented CAD, suggesting
that glimepiride may be the preferred sul-
fonylurea in those with underlying CAD.
The literature contains conﬂicting results
regarding whether an increased overall
mortality (or cardiovascular mortality)
risk accompanies the various sulfonyl-
ureas(12,17,18).Thisdiscrepancywould
support prospective studies to determine
whether the difference in pharmacologic
properties inherent to individual sulfo-
nylureas translates into differences in the
risk of adverse cardiovascular outcomes
and overall mortality, especially in pa-
tients with preexisting CAD.
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